Data periodFund holdingsSep 2026NSE prices23 Oct 2026Data status →
Days to sell half: 7.2 — selling half of every holding at 20% of each stock’s usual daily NSE trading, the time to get through 90% of the portfolio (Dec 2024). Takes days, not hours, to unwind. Small-cap comparison →
Shares of this fund’s disclosed Indian listed equity, valued at official NSE closing prices. Cash, debt, derivatives and overseas holdings are not included, so for a hybrid or debt fund these are shares of its equity part only. Not performance, and not a recommendation.
How concentrated it has been
23 priced months, Aug 2023 to Sep 2026 · at each month’s NSE closes
Top 10 holdings, share of equity
95.3% now, 86.3% in Sep 2025 · highest 99.6%, lowest 68.8%
Companies held
13 now, 14 in Sep 2025 · largest single holding 14.4% of equity
3 month(s) left out because under 90% of the companies held had an NSE price that month.
Sector mix
Share of the equity shown · NSE industry
Funds most like this one
Overlap of disclosed equity · the smaller share of each company both hold, added up
- quant Consumption Fundquant · 5 shared24.5%
- quant Aggressive Hybrid Fundquant · 2 shared21.5%
- quant Manufacturing Fundquant · 6 shared19.2%
- Bandhan Healthcare FundBandhan · 7 shared18.9%
- quant Multi Cap Fundquant · 8 shared18.4%
- quant Mid Cap Fundquant · 5 shared18.1%
- Bajaj Finserv Healthcare FundBajaj Finserv · 7 shared17.2%
- quant Flexi Cap Fundquant · 5 shared15.4%
Select one to see exactly what the two funds share. Index funds and ETFs tracking the same index overlap almost completely.
What changed in Sep 2026
This portfolio’s consecutive disclosures · evidenced adjustments applied
New positions
Complete exits
Largest increases
Largest reductions
Share quantities, not market values or cash flows.
Holdings by value
Sep 2026 · largest 100 · share of the equity shown
| Company | Sector | Size | Share of equity | Value | Shares held | Held since |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited | Healthcare | Mid Cap | 14.40% | 41.14 Cr | 0.01 Cr | Mar 2026 (6 mo) |
| Zydus Lifesciences Limited | Healthcare | Mid Cap | 13.94% | 39.84 Cr | 0.03 Cr | Aug 2026 (2 mo) |
| Strides Pharma Science Limited | Healthcare | Small Cap | 13.43% | 38.36 Cr | 0.03 Cr | Apr 2026 (5 mo) |
| Pfizer Limited | Healthcare | Small Cap | 10.95% | 31.28 Cr | 80,707 | May 2024 (19 mo) |
| Alivus Life Sciences Limited | Not classified | Small Cap | 9.23% | 26.38 Cr | 0.02 Cr | Jul 2024 (18 mo) |
| IPCA Laboratories Limited | Healthcare | Mid Cap | 8.88% | 25.39 Cr | 0.01 Cr | Jul 2026 (3 mo) |
| Aurobindo Pharma Limited | Healthcare | Mid Cap | 7.56% | 21.60 Cr | 0.01 Cr | Feb 2024 (22 mo) |
| Zydus Wellness Limited | Fast Moving Consumer Goods | Small Cap | 7.28% | 20.79 Cr | 0.04 Cr | Jul 2024 (18 mo) |
| Colgate Palmolive (India) Limited | Fast Moving Consumer Goods | Mid Cap | 5.13% | 14.64 Cr | 83,050 | Sep 2026 (1 mo) |
| Natco Pharma Limited | Healthcare | Small Cap | 4.47% | 12.78 Cr | 0.02 Cr | Sep 2026 (1 mo) |
| Dr. Reddy's Laboratories Limited | Healthcare | Large Cap | 3.47% | 9.90 Cr | 80,322 | Sep 2026 (1 mo) |
| LG Electronics India Limited | Consumer Durables | Large Cap | 0.88% | 2.52 Cr | 14,600 | Sep 2026 (1 mo) |
| Sumitomo Chemical India Limited | Chemicals | Small Cap | 0.39% | 1.11 Cr | 25,514 | Jul 2026 (3 mo) |
Half of its current holdings have been held for 3 disclosed months or more without a break. “By” means held in the first month we have for this fund, so possibly for longer. Counted over this fund’s own monthly disclosures; a merger (e.g. HDFC into HDFC Bank, July 2023) starts a new run for the surviving company.
Recent position changes
Latest 100 company-month records · evidenced adjustments applied
| Company | Month | Activity | Adjusted change |
|---|---|---|---|
| SMS Pharmaceuticals Limited | Sep 2026 | ▼ Complete exit | -0.08 Cr |
| Strides Pharma Science Limited | Sep 2026 | ▲ Increasing | +0.02 Cr |
| Concord Biotech Limited | Sep 2026 | ▼ Complete exit | -0.02 Cr |
| Natco Pharma Limited | Sep 2026 | ▲ New position | +0.02 Cr |
| Colgate Palmolive (India) Limited | Sep 2026 | ▲ New position | +83,050 |
| Dr. Reddy's Laboratories Limited | Sep 2026 | ▲ New position | +80,322 |
| Alivus Life Sciences Limited | Sep 2026 | ▼ Reducing | -55,050 |
| Zydus Wellness Limited | Sep 2026 | ▼ Reducing | -50,442 |
| LG Electronics India Limited | Sep 2026 | ▲ New position | +14,600 |
| IPCA Laboratories Limited | Sep 2026 | ▼ Reducing | -3,092 |
| HFCL LIMITED | Aug 2026 | ▼ Complete exit | -0.16 Cr |
| Aster DM Quality Care Limited | Aug 2026 | ▼ Complete exit | -0.04 Cr |
| Zydus Lifesciences Limited | Aug 2026 | ▲ New position | +0.03 Cr |
| Zydus Wellness Limited | Aug 2026 | ▼ Reducing | -0.02 Cr |
| Concord Biotech Limited | Aug 2026 | ▼ Reducing | -61,613 |
| Pfizer Limited | Aug 2026 | ▲ Increasing | +32,753 |
| HFCL LIMITED | Jul 2026 | ▼ Reducing | -0.04 Cr |
| IPCA Laboratories Limited | Jul 2026 | ▲ New position | +0.01 Cr |
| GlaxoSmithKline Pharmaceuticals Limited | Jul 2026 | ▲ Increasing | +0.01 Cr |
| Max Healthcare Institute Limited | Jul 2026 | ▼ Complete exit | -70,148 |
| Sumitomo Chemical India Limited | Jul 2026 | ▲ New position | +25,514 |
| HFCL LIMITED | Apr 2026 | ▲ New position | +0.22 Cr |
| SMS Pharmaceuticals Limited | Apr 2026 | ▼ Reducing | -0.01 Cr |
| Concord Biotech Limited | Apr 2026 | ▼ Complete exit | -83,472 |
| Anthem Biosciences Limited | Apr 2026 | ▼ Reducing | -38,175 |
| Adani Enterprises Limited | Apr 2026 | ▼ Complete exit | -11,399 |
| Strides Pharma Science Limited | Apr 2026 | ▲ New position | +10,138 |
| HDFC Life Insurance Company Limited | Oct 2025 | ▼ Complete exit | -0.03 Cr |
| Aster DM Quality Care Limited | Oct 2025 | ▼ Reducing | -0.02 Cr |
| RPG Life Sciences Limited | Oct 2025 | ▼ Complete exit | -0.02 Cr |
| Adani Enterprises Limited | Oct 2025 | ▲ New position | +94,996 |
| Godrej Properties Limited | Oct 2025 | ▲ New position | +47,015 |
| SMS Pharmaceuticals Limited | Oct 2025 | ▲ Increasing | +43,932 |
| Divi's Laboratories Limited | Oct 2025 | ▲ New position | +20,424 |
| Zydus Lifesciences Limited | Apr 2025 | ▼ Complete exit | -0.03 Cr |
| IPCA Laboratories Limited | Apr 2025 | ▼ Complete exit | -0.02 Cr |
| SMS Pharmaceuticals Limited | Apr 2025 | ▲ Increasing | +0.02 Cr |
| Lupin Limited | Apr 2025 | ▲ New position | +56,976 |
| Divi's Laboratories Limited | Apr 2025 | ▲ Increasing | +1,073 |
| Reliance Industries Limited | Feb 2025 | ▼ Reducing | -24,390 |
| Pfizer Limited | Feb 2025 | ▼ Reducing | -9,115 |
| RPG Life Sciences Limited | Feb 2025 | ▼ Reducing | -2,538 |
| Suven Life Sciences Limited | Jan 2025 | ▼ Complete exit | -0.08 Cr |
| Aarti Pharmalabs Limited | Jan 2025 | ▼ Complete exit | -0.03 Cr |
| GlaxoSmithKline Pharmaceuticals Limited | Jan 2025 | ▼ Complete exit | -0.01 Cr |
| Divi's Laboratories Limited | Jan 2025 | ▲ New position | +61,300 |
| Torrent Pharmaceuticals Limited | Jan 2025 | ▲ Increasing | +52,900 |
| Thyrocare Technologies Limited | Jan 2025 | ▼ Complete exit | -40,794 |
| Alembic Pharmaceuticals Limited | Jan 2025 | ▼ Complete exit | -40,380 |
| Acutaas Chemicals Limited | Jan 2025 | ▼ Complete exit | -17,566 |
| IPCA Laboratories Limited | Jan 2025 | ▲ Increasing | +11,800 |
| Zydus Lifesciences Limited | Jan 2025 | ▲ Increasing | +11,174 |
| Sanofi Consumer Healthcare India Limited | Jan 2025 | ▼ Complete exit | -7,900 |
| Viyash Scientific Limited | Oct 2024 | ▲ Increasing | +0.02 Cr |
| Thyrocare Technologies Limited | Oct 2024 | ▲ New position | +40,794 |
| Torrent Pharmaceuticals Limited | Oct 2024 | ▲ New position | +34,300 |
| Divi's Laboratories Limited | Oct 2024 | ▼ Reducing | -19,051 |
| Acutaas Chemicals Limited | Oct 2024 | ▲ New position | +12,500 |
| Alivus Life Sciences Limited | Oct 2024 | ▲ Increasing | +184 |
| Dishman Carbogen Amcis Limited | May 2024 | ▼ Complete exit | -0.06 Cr |
| Indoco Remedies Limited | May 2024 | ▼ Complete exit | -0.03 Cr |
| Jubilant Pharmova Limited | May 2024 | ▼ Complete exit | -0.03 Cr |
| Zydus Lifesciences Limited | May 2024 | ▲ New position | +0.02 Cr |
| Kopran Limited | May 2024 | ▼ Complete exit | -0.01 Cr |
| Aarti Pharmalabs Limited | May 2024 | ▲ Increasing | +0.01 Cr |
| Reliance Industries Limited | May 2024 | ▼ Complete exit | -89,350 |
| Aster DM Quality Care Limited | May 2024 | ▲ New position | +86,164 |
| Pfizer Limited | May 2024 | ▲ New position | +54,346 |
| Dr. Reddy's Laboratories Limited | May 2024 | ▲ New position | +25,000 |
| Aurobindo Pharma Limited | May 2024 | ▼ Reducing | -6,200 |
| GlaxoSmithKline Pharmaceuticals Limited | May 2024 | ▼ Reducing | -5,000 |
| Indraprastha Medical Corporation Limited | Apr 2024 | ▲ New position | +0.07 Cr |
| Metropolis Healthcare Limited | Apr 2024 | ▼ Complete exit | -85,000 |
| GlaxoSmithKline Pharmaceuticals Limited | Apr 2024 | ▲ Increasing | +60,000 |
| Biocon Limited | Mar 2024 | ▼ Complete exit | -0.07 Cr |
| SMS Pharmaceuticals Limited | Mar 2024 | ▲ New position | +0.06 Cr |
| Gujarat Themis Biosyn Limited | Mar 2024 | ▲ New position | +0.03 Cr |
| Kopran Limited | Mar 2024 | ▲ New position | +0.01 Cr |
| Kovai Medical Center & Hospital Limited | Mar 2024 | ▲ Increasing | +4,100 |
| Dishman Carbogen Amcis Limited | Feb 2024 | ▲ New position | +0.06 Cr |
| Aurobindo Pharma Limited | Feb 2024 | ▲ New position | +0.02 Cr |
| Sun Pharmaceutical Industries Limited | Feb 2024 | ▼ Complete exit | -0.01 Cr |
| Poly Medicure Limited | Feb 2024 | ▲ Increasing | +0.01 Cr |
| Metropolis Healthcare Limited | Feb 2024 | ▲ New position | +85,000 |
| Kovai Medical Center & Hospital Limited | Feb 2024 | ▲ New position | +35,300 |
| Reliance Industries Limited | Feb 2024 | ▲ Increasing | +8,000 |
| Brooks Laboratories Limited | Nov 2023 | ▲ Increasing | +0.01 Cr |
| Kopran Limited | Nov 2023 | ▼ Complete exit | -0.01 Cr |
| Granules India Limited | Nov 2023 | ▲ Increasing | +70,000 |
| Alembic Pharmaceuticals Limited | Nov 2023 | ▼ Complete exit | -52,000 |
| Life Insurance Corporation Of India | Nov 2023 | ▲ New position | +45,000 |
| Aster DM Quality Care Limited | Nov 2023 | ▼ Reducing | -2,600 |
Changes compare consecutive month-end disclosures for this portfolio only.